ChimerisMonitor
The intuitive software for automated chimerism analysis

Features
- Simplifies and speeds up data analysis for BIOTYPE chimerism kits
- Automates critical and time-consuming steps from allelic call to chimerism value calculation
- Includes an extensive control concept for run and sample validation
- Builds a patient database encompassing preTx genotypes and postTx chimerism kinetics
- Available in 2 product variants:
ChimerisMonitor IVD with an IVD-certified workflow for robust and reliable data analysis
ChimerisMonitor RUO for reanalysis of critical data sets outside the IVD-certified workflow
The software is available as the IVDR-compliant ChimerisMonitor IVD application, which, in combination with the Mentype® Chimera® and Mentype® DIPscreen assays, offers a complete IVD-certified workflow from PCR set-up to data analysis. The ChimerisMonitor RUO software can additionally be used to analyze the Mentype® DIPquant assays and critical data sets with, for example, alternative sample types. By installing both applications, a synchronized database is created, which reduces effort and still provides a clear differentiation between the data from both software.
Product Specifications
- Assays analyzed
- Mentype® Chimera®, Mentype® DIPscreen, Mentype®DIPquant*
- Status
- CE-IVD or For research use only (RUO)*
- Data input
- fsa/hidfiles, txt files
- Data visualizing
- Electropherogram, calculation results, overview about results in 1 sample sheet, PDF report with longitudinal chimerism kinetics
- Data processing
- Database included for saving of pre-transplant and post-transplant data
- Turnaround time
- 5 min per sample
Product References
- Al-Akioui Sanz, K. et al. Familial CD45RA– T cells to treat severe refractory infections in immunocompromised patients. Front. Med. 10. https://doi.org/10.3389/fmed.2023.1083215 (2023)
- Ferreras, C. et al. Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210). Cytotherapy 26, 25-35, https://doi.org/10.1016/j.jcyt.2023.10.002 (2024)
- Pérez-Martínes, A. et al. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). EClinicalMedicine 39. https://doi.org/10.1016/j.eclinm.2021.101086 (2021)
Resources
Ordering Information
ChimerisMonitor IVD
Cat. No.: 46-14800-0000
Status: CE-IVD
ChimerisMonitor RUO
Cat. No.: 46-14801-0000
Status: RUO*
*RUO - Research Use Only products must be validated by the customer with clinically relevant material for diagnostic purposes.